NEUROFIBROMATOSIS TYPE 2
Clinical trials for NEUROFIBROMATOSIS TYPE 2 explained in plain language.
Never miss a new study
Get alerted when new NEUROFIBROMATOSIS TYPE 2 trials appear
Sign up with your email to follow new studies for NEUROFIBROMATOSIS TYPE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising meningioma drug trial halted early – what we know
Disease control TerminatedThis study tested a drug called REC-2282 in people with a rare genetic condition (NF2) that causes brain tumors called meningiomas. The trial aimed to see if the drug could slow tumor growth. It was stopped early, but the results may still help researchers understand how to treat…
Matched conditions: NEUROFIBROMATOSIS TYPE 2
Phase: PHASE2, PHASE3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 07:23 UTC
-
New drug cocktail trial targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested combinations of drugs (bevacizumab, temsirolimus, valproic acid, or cetuximab) in 154 adults with advanced cancers or certain non-cancerous diseases that are progressive and life-limiting. The main goal was to find the safest doses and understand sid…
Matched conditions: NEUROFIBROMATOSIS TYPE 2
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:23 UTC
-
Experimental drug AR-42 explored for rare brain tumors – but study ends early
Knowledge-focused TerminatedThis early-stage study tested a drug called AR-42 in 7 adults with vestibular schwannoma or meningioma (types of brain tumors) who were already scheduled for surgery. The goal was to see if the drug could lower the activity of a protein called p-AKT inside the tumors. The study w…
Matched conditions: NEUROFIBROMATOSIS TYPE 2
Phase: EARLY_PHASE1 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Knowledge-focused
Last updated May 26, 2026 07:44 UTC